Alzheimer’s Diagnosis in Her 30s Sparks Insurance Battle
Alzheimer’s disease is often associated with older adults, but a Massachusetts woman, Haritha Sudanagunta, received a devastating diagnosis in her thirties. Her fight for access to potentially life-altering treatment has highlighted issues with insurance coverage and age-based restrictions for emerging Alzheimer’s therapies.
A Rare and Early Diagnosis
Haritha Sudanagunta, a lawyer with a background in bioengineering and a former Jeopardy! contestant, began experiencing memory and speech issues in her mid-thirties. After years of testing, she received a diagnosis of early-onset Alzheimer’s disease. “I think it was shock, right? And grief,” her husband, Robert MacLean, said. “Your world falls down when you hear something like that.” Early-onset Alzheimer’s, defined as symptoms beginning before age 60, affects approximately 5-10% of individuals with the disease .
New Treatments Offer Hope
Despite the grim diagnosis, hope emerged with the development of new medications like lecanemab and donanemab. These therapies aim to gradual the progression of Alzheimer’s by targeting amyloid plaques in the brain, which impair cognitive function. Dr. P. Monroe Butler at Brigham and Women’s Hospital determined that donanemab, marketed as Kisunla, was the most appropriate treatment for Sudanagunta. “These infusion therapies actually dissolve the amyloid — the Alzheimer’s plaques — and slow the disease down modestly, but it’s the first time we’ve been able to do that,” Dr. Butler explained . Studies have shown donanemab can reduce plaque buildup by up to 84% in patients with mild dementia symptoms .
Insurance Denial Based on Age
The cost of donanemab is significant – approximately $32,000 per year. Still, Sudanagunta’s insurance, Wellpoint, initially denied coverage, citing her age as the primary reason. The insurance company repeatedly stated she needed to be at least 60 years classic to qualify for the drug, without providing a clear justification . Dr. Butler strongly disagreed with this decision, emphasizing that “the earlier we’re able to start treatment, the better the results are that we’re seeing. Time is brain.”
Arbitrary Age Limits and FDA Approval
MacLean discovered that Wellpoint’s age range for donanemab (60-85) mirrored the age range of participants in the drug’s clinical trial. However, the Food and Drug Administration (FDA) approval of donanemab did not include any age restrictions .
Advocacy Leads to Coverage
Driven to secure treatment for his wife, MacLean contacted his employer, elected officials, and the media. This advocacy ultimately led Wellpoint to reverse its decision, approving coverage for Sudanagunta’s donanemab treatment, though without offering an explanation for the initial denial .
A Call for Policy Change
Despite the positive outcome for Sudanagunta, she and MacLean believe the insurance process remains flawed, lacking transparency and flexibility. They hope their experience will prompt Wellpoint to reconsider its age limits and ensure equitable access to treatment for all Alzheimer’s patients. Wellpoint stated that the initial denial was due to limited clinical evidence for the drug in younger patients, but ultimately approved the medication after further review .
Resources for Alzheimer’s Disease
For more information and resources on Alzheimer’s disease and related dementias, visit the Massachusetts government website: Alzheimer’s Disease and Related Dementias – Mass.gov.
Keep reading